DENTSPLY SIRONA (XRAY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.52
- Estimate
- $0.35
- Surprise
- +50.1%
- Revenue (period 2026-06-30)
- $898.0M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
DENTSPLY SIRONA (XRAY) beat the $0.35 estimate with diluted EPS of $0.52 — a large 50.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates XRAY Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +50.1% surprise compares with a +6.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (3.5 < 4.0)
- Reward/Risk 1.1:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.35
- Price target
- $12.35
- Stop
- $10.63
- Upside to target
- +8.8%
- Reward-to-risk
- 1.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
XRAY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $2.28B
- P/E (fwd)
- 7.5
- 52-week range
- $9.41–$14.86
- Off 52-week high
- 23.6%
- RSI (14)
- 47
- Volume vs avg
- 0.95×
- Score today
- 5.0/10